Study of the Effect of Glutamine Supplementation on Chemotherapy Induced Toxicities in Breast Cancer Patients- A Prospective, Randomised, Single Blind, Three Arm, Phase Four Prevention Trial
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 23
- 试验地点
- 2
- 主要终点
- Reduction in toxicity
研究概览
简要总结
Glutamine, a non essential branched chain amino acid, is most important non toxic nitrogen carrier in body. It participates in variety of physiological functions. It is a major fuel source of enterocytes and is a substrate for gluconeogenesis in kidney, lymphocytes, and monocytes. It is also a nutrient in muscle protein metabolism in response to infection, inflammation and muscle trauma. The significance of glutamine to metabolic homeostasis becomes evident during periods of stress, when it becomes a conditionally essential amino acid. Role of glutamine as protective agent in hepato-biliary dysfunction, in maintaining mucosal integrity of the Gastrointestinal tract following its administration in patient with major bowel surgery as a supplement and part of TPN in critically ill patients and in patients of septicemia, is well established. However the role of glutamine supplementation in reducing or preventing chemotherapeutic agents induced toxicity in cancer patients is controversial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 85 Years(Adult, Older Adult)
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •The patients > 18 years of age
- •Histologically or cytologically proven breast cancer
- •Receiving CEF chemotherapy cycles presently or in the past
- •The patients who will give informed consent to participate in the study
- •Patients must have sufficient organ and marrow function
- •Stage 1 neuropathy, subclinical neuropathy, surgery induced neuropathy
排除标准
- •Pregnancy
- •Clinical/biochemical severe liver failure
- •Clinical/biochemical severe renal dysfunction
- •Refusal to participate in the study
- •Patients who have received prior chemotherapy with paclitaxel.
- •Patients who have neuropathy due to any known systemic or metabolic causes like diabetes, leprosy, nutritional deficiency induced (vit. B12) etc
研究组 & 干预措施
2
Intravenous glutamine
干预措施: IV Glutamine (Dietary Supplement)
1
10 patients (30 cycles) of chemotherapy will receive placebo
3
Oral Glutamine
干预措施: Glutamine (Dietary Supplement)
结局指标
主要结局
Reduction in toxicity
时间窗: 3 weeks
次要结局
- Serum level of creatinine kinase and LDH(3 weeks)
研究者
Manoj Pandey
Professor, Surgical Oncology
Banaras Hindu University
